Wyniki wyszukiwania

1

Evidence of TWIST1 and transforming growth factor-beta1 aberrant expressions as novel therapeutic targets in modulating the severity of osteoarthritis with focus on biologic agents

100%

Ye C., Ye J., Wu H., Zhang F., Liu Y.

Journal of Physiology and Pharmacology

|

2020

|

tom 71

|

nr 6

2

Analysis of the correlations between oxidative stress, gelatinases and their tissue inhibitors in the human subjects with obstructive sleep apnea syndrome

84%

Hopps E., Lo Presti R., Montana M., Canino B., Calandrino V., Caimi G.

Journal of Physiology and Pharmacology

|

2015

|

tom 66

|

nr 6

3

Mechanisms promoting physiological cells progression into tumorigenesis

67%

Korbut E., Ptak-Belowska A., Brzozowski T.

Journal of Physiology and Pharmacology

|

2012

|

tom 63

|

nr 6

4

LAM cells biology and lymphangioleiomyomatosis

67%

Grzegorek I., Drozdz K., Podhorska-Okolow M., Szuba A., Dziegiel P.

Folia Histochemica et Cytobiologica

|

2013

|

tom 51

|

nr 1

5

The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer

67%

Groblewska M., Siewko M., Mroczko B., Szmitkowski M.

Folia Histochemica et Cytobiologica

|

2012

|

tom 50

|

nr 1

6

Antiangiogenic gene therapy in inhibition of metastasis

67%

Szala S., Szary J., Cichon T., Sochanik A.

Acta Biochimica Polonica

|

2002

|

tom 49

|

nr 2

This short review attempts to demonstrate the usefulness of antiangiogenic gene therapy in achieving inhibition of growth in experimentally-induced metastases. Certain normal tissues (for example skeletal muscle) may be used in vivo, after genetic modification, as a "bioreactor", able to produce and secrete into the bloodstream proteins known to exert antiangiogenic effects. By inhibiting neoangiogenesis these proteins would thus prevent the development of metastases. The review discusses also the perspectives of antimetastatic therapy based on certain types of allogenic cells (for example myoblasts and fibroblasts) that had been genetically modified and then microencapsulated. The strategy of encapsulation is aimed at protecting the modified cells secreting antiangiogenic factors from being eliminated by the immune system. Secretion of antiangiogenic proteins by these microencapsulated cells can be controlled with inducible promoters. Antiangiogenic genes remaining under the transcriptional control of such promoters may be switched on and off using antibiotics, such as tetracycline derivatives, or steroid hormones.

Ograniczanie wyników

Evidence of TWIST1 and transforming growth factor-beta1 aberrant expressions as novel therapeutic targets in modulating the severity of osteoarthritis with focus on biologic agents

Analysis of the correlations between oxidative stress, gelatinases and their tissue inhibitors in the human subjects with obstructive sleep apnea syndrome

Mechanisms promoting physiological cells progression into tumorigenesis

LAM cells biology and lymphangioleiomyomatosis

The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer

Antiangiogenic gene therapy in inhibition of metastasis